Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 7 | 2019 | 813 | 1.190 |
Why?
|
| Mastectomy, Segmental | 4 | 2022 | 922 | 0.930 |
Why?
|
| Breast Neoplasms | 10 | 2022 | 19798 | 0.900 |
Why?
|
| Radiometry | 2 | 2022 | 810 | 0.710 |
Why?
|
| Asbestos | 1 | 2020 | 243 | 0.680 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2014 | 68 | 0.650 |
Why?
|
| Inflammasomes | 3 | 2016 | 419 | 0.630 |
Why?
|
| Lymphedema | 1 | 2022 | 414 | 0.610 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2022 | 1832 | 0.610 |
Why?
|
| Refugees | 1 | 2022 | 449 | 0.570 |
Why?
|
| Pleural Neoplasms | 1 | 2020 | 619 | 0.530 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 262 | 0.510 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1231 | 0.510 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 295 | 0.470 |
Why?
|
| Radiosurgery | 1 | 2021 | 1347 | 0.460 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 539 | 0.440 |
Why?
|
| Doxorubicin | 3 | 2014 | 2238 | 0.430 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2603 | 0.410 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2285 | 0.400 |
Why?
|
| Quinazolines | 1 | 2014 | 1426 | 0.330 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 1603 | 0.310 |
Why?
|
| Piperidines | 1 | 2014 | 1588 | 0.300 |
Why?
|
| Lung Diseases | 1 | 2016 | 1890 | 0.290 |
Why?
|
| Dentigerous Cyst | 1 | 2004 | 21 | 0.280 |
Why?
|
| Focal Infection, Dental | 1 | 2004 | 26 | 0.280 |
Why?
|
| Pneumonia | 1 | 2016 | 2071 | 0.270 |
Why?
|
| Mediastinitis | 1 | 2004 | 51 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 8864 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2021 | 3535 | 0.260 |
Why?
|
| Mandibular Diseases | 1 | 2004 | 124 | 0.250 |
Why?
|
| Mastectomy | 2 | 2022 | 1671 | 0.250 |
Why?
|
| Silicon Dioxide | 2 | 2016 | 257 | 0.240 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 11244 | 0.240 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2021 | 902 | 0.240 |
Why?
|
| Seroma | 1 | 2022 | 66 | 0.230 |
Why?
|
| Syria | 1 | 2022 | 70 | 0.230 |
Why?
|
| Turkey | 1 | 2022 | 229 | 0.220 |
Why?
|
| GPI-Linked Proteins | 2 | 2013 | 463 | 0.220 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8941 | 0.210 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 8756 | 0.200 |
Why?
|
| Spectrum Analysis | 1 | 2022 | 450 | 0.200 |
Why?
|
| Axilla | 1 | 2022 | 534 | 0.190 |
Why?
|
| Mucositis | 1 | 2020 | 96 | 0.190 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 12446 | 0.190 |
Why?
|
| Necrosis | 2 | 2021 | 1632 | 0.190 |
Why?
|
| Hormones | 1 | 2022 | 847 | 0.170 |
Why?
|
| Algorithms | 1 | 2019 | 13668 | 0.170 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 432 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 654 | 0.170 |
Why?
|
| Asbestos, Crocidolite | 2 | 2013 | 19 | 0.160 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 525 | 0.150 |
Why?
|
| Lymph Node Excision | 1 | 2022 | 1182 | 0.150 |
Why?
|
| Humans | 30 | 2022 | 709431 | 0.150 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 179 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 505 | 0.140 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 335 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 620 | 0.140 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2014 | 38 | 0.140 |
Why?
|
| Radiation Oncology | 1 | 2020 | 504 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2022 | 71151 | 0.130 |
Why?
|
| Zeolites | 1 | 2013 | 6 | 0.130 |
Why?
|
| Transportation | 1 | 2015 | 210 | 0.130 |
Why?
|
| Female | 16 | 2022 | 377269 | 0.130 |
Why?
|
| Curcumin | 1 | 2014 | 98 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2020 | 1627 | 0.120 |
Why?
|
| Brachytherapy | 1 | 2021 | 1284 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3431 | 0.120 |
Why?
|
| Autocrine Communication | 1 | 2013 | 185 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2137 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 1528 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1575 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2022 | 2765 | 0.100 |
Why?
|
| Microspheres | 1 | 2013 | 799 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 681 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2014 | 1890 | 0.100 |
Why?
|
| Piperazines | 1 | 2020 | 2606 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 970 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 1945 | 0.090 |
Why?
|
| Epithelium | 1 | 2013 | 1740 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5233 | 0.090 |
Why?
|
| Pyridines | 1 | 2020 | 2875 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11269 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 3660 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2012 | 716 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 17087 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2020 | 61963 | 0.080 |
Why?
|
| Cell Survival | 2 | 2014 | 6184 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 13363 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 4020 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 9857 | 0.070 |
Why?
|
| Particulate Matter | 1 | 2016 | 2278 | 0.070 |
Why?
|
| African Americans | 1 | 2021 | 5194 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6830 | 0.070 |
Why?
|
| Clindamycin | 1 | 2004 | 140 | 0.070 |
Why?
|
| Cytokines | 3 | 2014 | 7214 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1956 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 2903 | 0.060 |
Why?
|
| Aged | 8 | 2020 | 162592 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 5392 | 0.060 |
Why?
|
| RNA Interference | 1 | 2013 | 3027 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8053 | 0.060 |
Why?
|
| Sarcoma | 1 | 2014 | 1856 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2014 | 8737 | 0.060 |
Why?
|
| Mice, SCID | 3 | 2013 | 2866 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2014 | 5177 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2004 | 309 | 0.060 |
Why?
|
| Middle Aged | 8 | 2021 | 215428 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3163 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3276 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 58752 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 2282 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 29148 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 11553 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 1549 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2013 | 3756 | 0.050 |
Why?
|
| Risk Factors | 3 | 2022 | 70264 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 4853 | 0.050 |
Why?
|
| Radiodermatitis | 1 | 2019 | 60 | 0.050 |
Why?
|
| Lymphatic Irradiation | 1 | 2019 | 104 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13763 | 0.050 |
Why?
|
| Drainage | 1 | 2004 | 1135 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 4996 | 0.040 |
Why?
|
| Surface Properties | 1 | 2020 | 1214 | 0.040 |
Why?
|
| Glossectomy | 1 | 2017 | 52 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2013 | 1932 | 0.040 |
Why?
|
| Apoptosis | 1 | 2014 | 10133 | 0.040 |
Why?
|
| Animals | 7 | 2020 | 170647 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2020 | 2012 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 559 | 0.040 |
Why?
|
| Rectum | 1 | 2021 | 894 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2017 | 214 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 757 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 2963 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 20307 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2014 | 216 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 450 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2019 | 3000 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2013 | 271 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 308 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 20421 | 0.030 |
Why?
|
| Male | 6 | 2021 | 351848 | 0.030 |
Why?
|
| Mesentery | 1 | 2012 | 210 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2012 | 342 | 0.030 |
Why?
|
| Time Factors | 3 | 2020 | 41295 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 636 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 212298 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 324 | 0.020 |
Why?
|
| Rats | 2 | 2020 | 25068 | 0.020 |
Why?
|
| Mice | 5 | 2014 | 80950 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 6012 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3740 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18384 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2443 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 1722 | 0.020 |
Why?
|
| Gadolinium | 1 | 2012 | 907 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 4069 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 1663 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 608 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3904 | 0.020 |
Why?
|
| Cattle | 1 | 2012 | 4024 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 2137 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 7071 | 0.020 |
Why?
|
| Palliative Care | 1 | 2020 | 3274 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 6659 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4976 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13595 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5508 | 0.020 |
Why?
|
| Registries | 1 | 2020 | 8019 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 1990 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 2426 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 4090 | 0.020 |
Why?
|
| Prevalence | 1 | 2020 | 14849 | 0.020 |
Why?
|
| Lung | 1 | 2022 | 9617 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 4720 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 20587 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 16161 | 0.010 |
Why?
|
| Logistic Models | 1 | 2017 | 13622 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 6922 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 11384 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 22944 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 7988 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39394 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 23519 | 0.010 |
Why?
|
| Macrophages | 1 | 2013 | 5774 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 13351 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10858 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8733 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 9584 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 50734 | 0.010 |
Why?
|
| Inflammation | 1 | 2013 | 9948 | 0.010 |
Why?
|
| United States | 1 | 2021 | 67177 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 23985 | 0.010 |
Why?
|
Concepts
(192)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_